1989
DOI: 10.1001/archderm.125.8.1093
|View full text |Cite
|
Sign up to set email alerts
|

Merkel cell carcinoma. A successful treatment with tumor necrosis factor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
8
0
1

Year Published

1991
1991
2019
2019

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 0 publications
1
8
0
1
Order By: Relevance
“…A previous history or concomitant squamous cell carcinoma (SCC) is identified in one third of patients with neuroendocrine carcinoma of the skin leading some to speculate on a common carcinogenic influence 14 such as ultraviolet light 15 . Further support for this hypothesis is the finding that 16 of 24 (66%) neuroendocrine carcinoma of the skin of the lower extremity occurred in females 2–4,10,12,15–31 . This closely parallels the observation in malignant melanoma, where three quarters of the tumors of the lower extremities occur in women 32 .…”
Section: Discussionsupporting
confidence: 58%
“…A previous history or concomitant squamous cell carcinoma (SCC) is identified in one third of patients with neuroendocrine carcinoma of the skin leading some to speculate on a common carcinogenic influence 14 such as ultraviolet light 15 . Further support for this hypothesis is the finding that 16 of 24 (66%) neuroendocrine carcinoma of the skin of the lower extremity occurred in females 2–4,10,12,15–31 . This closely parallels the observation in malignant melanoma, where three quarters of the tumors of the lower extremities occur in women 32 .…”
Section: Discussionsupporting
confidence: 58%
“…55 Tumor necrosis factor also succeeded in achieving complete remission of an inoperable MCC after daily administration of 1.5 × 10 6 units locally for 12 days. 47 In contrast, the antitumoral activity of somatostatin seems negligible. Treatment of neuroendocrine tumors with somatostatin produced complete remission in only 3% of cases.…”
Section: Chemoimmunotherapy For Stage II and Iii Diseasementioning
confidence: 99%
“…1,32,32 Immune therapy for MCC has only infrequently been attempted, including that using tumor necrosis factor-α , interferon (INF)-α and INF-γ , but has shown some potential, and may have a role as an adjuvant, especially with improved staging and better patient selection. 33,34…”
Section: Editorial Commentsmentioning
confidence: 99%